For a correct assessment of health consequences of inhaled aerosols as a function of dose, whether for environmental, occupational or therapeutic agents, knowledge of their deposition distribution in the respiratory tract and subsequent clearance is important. The objective of this study is to model particle clearance at bronchial airway bifurcation level and to analyze the combined effect of deposition and clearance. For this purpose, a numerical model has been implemented. Air and mucus flow fields were computed in a model bronchial airway bifurcation. Inhaled particles with 1 and 10 µm aerodynamic diameters were tracked to determine deposition and clearance patterns. Simulation results revealed the existence of a slow clearance zone around the peak of the airway bifurcation causing delayed clearance of the particles depositing or entering here. Particles clearing up from the deeper airways and crossing the studied bifurcation do not accumulate in this zone, because of their tendency to avoid it. The average residence time of these particles was around 20 min independently of particle size (whether it is 1 or 10 µm). However, as a result of the superposition of deposition and clearance mechanisms, the final spatial distribution of particles deposited primarily in the target bifurcation is size dependent, because deposition is size specific. Although deposition density of particles deposited in the slow clearance area is one-two orders of magnitude higher than the average deposition density, these values are reduced by clearance by the factors of 4-7, depending on the particle size and the surface area of the selected slow clearance zone. In conclusion, although particle deposition is inhomogeneous, clearance can significantly decrease the degree of spatial non-uniformity of the particles. Therefore, for a correct assessment of doses at local levels, it is important to consider both deposition and clearance. Although future research may overwrite some of the model assumptions on the nature of mucus, the authors think that most of the current predictions will hold.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/08958378.2013.815666 | DOI Listing |
Background: The Centiloid method (CL) was introduced as a tracer-independent measure for cortical amyloid load and is now commonly used in Alzheimer's disease (AD) clinical trials. To facilitate its implementation into clinical settings, the AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations of the Centiloid scale, which has been submitted to the European Medicine Agency for endorsement as a Biomarker Qualification Opinion.
Method: Screening of the literature was performed on the 7/11/23 on PubMed to identify articles mentioning "Centiloid".
Background: Alzheimer's disease (AD) progression is often characterized by the accumulation of amyloid and tau proteins, which can be linked to impaired brain clearance mechanisms, including the glymphatic system. Our research evaluates noninvasive MRI-based indicators of brain clearance functionality, such as choroid plexus volume (CPV), lateral ventricular volume (LVV), and the perivascular space diffusivity index (ALPS index), throughout various stages of AD.
Method: We analyzed MRI data measuring CPV, LVV, and ALPS index from participants categorized as amyloid-beta (Aβ)- negative healthy controls (HC), Aβ-positive HC, Aβ-negative subjective cognitive decline (SCD), Aβ-positive SCD, mild cognitive impairment (MCI), and AD, using the Alzheimer's Disease Neuroimaging Initiative database.
Alzheimers Dement
December 2024
cheonan chungmu hospital, cheonan si, Korea, Republic of (South).
Background: Vascular contributions to dementia & Alzheimer's disease are increasing recognized. Recent studies have suggested that blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction, including the early clinical stages of AD. Apolipoprotein E4(APOE4), the major AD susceptibility gene, leads to accelerated blood-brain barrier breakdown & degeneration of brain capillary pericyte that maintain blood-brain barrier integrity.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
GE HealthCare, Amersham, United Kingdom; UCL Centre for Medical Image Computing, London, United Kingdom.
Background: The Centiloid method (CL) was introduced as a tracer-independent measure for cortical amyloid load and is now commonly used in Alzheimer's disease (AD) clinical trials. To facilitate its implementation into clinical settings, the AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations of the Centiloid scale, which has been submitted to the European Medicine Agency for endorsement as a Biomarker Qualification Opinion.
Method: Screening of the literature was performed on the 7/11/23 on PubMed to identify articles mentioning "Centiloid".
Alzheimers Dement
December 2024
Departments of Psychiatry and Behavioral Sciences, Neurology, and Epidemiology, University of California San Francisco, San Francisco, CA, USA.
Background: Older age is associated with sleep disruptions and the aggregation of pathological tau in the medial temporal lobe (MTL). Associations between sleep disruptions and the progression of Alzheimer's disease (AD) have been widely demonstrated. However, data addressing the association of objectively measured sleep apnea to tau deposition beyond the MTL in cognitively unimpaired older adults are limited.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!